Randal Swenson, MD
Otolaryngology/Facial Plastic Surgery · Slc, UTNPI 1578522959
Payments from drug & device makers
Across 77 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$330
- Sanofi$327
- AbbVie$179
- AstraZeneca$139
- Optinose US, Inc.$117
- Inspire Medical Systems, Inc.$98
- plus $531 from 16 others
What the payments were for
- Food & beverage$1,70899%
- Other$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $330 |
| Sanofi | 16 | $327 |
| AbbVie(2 entities) | 4 | $179 |
| AstraZeneca | 6 | $139 |
| Optinose US, Inc. | 7 | $117 |
| Inspire Medical Systems, Inc. | 5 | $98 |
| GSK | 5 | $89 |
| Revance Therapeutics, Inc. | 1 | $60 |
| Stryker | 3 | $56 |
| Medtronic | 1 | $39 |
| Innovation Technologies Inc | 1 | $35 |
| Galderma Laboratories, L.p. | 2 | $32 |
| Aerin Medical Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Merz North America, Inc. | 2 | $30 |
| Grifols USA, LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Acell, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Intersect ENT, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $16 |
| Welch Allyn | 1 | $13 |
How this compares
Too few otolaryngology/facial plastic surgery providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 22 | $909 |
| Cefdinir | 15 | $301 |
| Fluticasone Propionate | 13 | $212 |
| Famotidine | 20 | $164 |
| Ondansetron OdtOndansetron | 14 | $123 |
| Methylprednisolone | 12 | $106 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology/facial plastic surgery in Slc
- Scott ThompsonLayton$2K
- James ManningDraper$375
- Jordan WallinSt George$305
- Amir AllakWest Jordan$34
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.